Latest BML Capital Management, LLC Stock Portfolio
BML Capital Management, LLC Performance:
2025 Q3: 8.13%YTD: -4.86%2024: 10.89%
Performance for 2025 Q3 is 8.13%, and YTD is -4.86%, and 2024 is 10.89%.
About BML Capital Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, BML Capital Management, LLC reported an equity portfolio of $109.2 Millions as of 30 Sep, 2025.
The top stock holdings of BML Capital Management, LLC are ACRS, AVIR, ADVM. The fund has invested 24.8% of it's portfolio in ACLARIS THERAPEUTICS INC and 19.9% of portfolio in ATEA PHARMACEUTICALS INC.
The fund managers got completely rid off ESSA PHARMA INC (EPIX), IKENA ONCOLOGY INC (IKNA) and MILESTONE PHARMACEUTICALS IN (MIST) stocks. They significantly reduced their stock positions in LISATA THERAPEUTICS INC (CLBS) and ATEA PHARMACEUTICALS INC (AVIR). BML Capital Management, LLC opened new stock positions in CONNECT BIOPHARMA HLDGS LTD, IMAGENEBIO INC (IKNA) and ATHIRA PHARMA INC (ATHA). The fund showed a lot of confidence in some stocks as they added substantially to INSTIL BIO INC (TIL), KEZAR LIFE SCIENCES INC (KZR) and PMV PHARMACEUTICALS INC (PMVP).
The top stock holdings of BML Capital Management, LLC are ACRS, AVIR, ADVM. The fund has invested 24.8% of it's portfolio in ACLARIS THERAPEUTICS INC and 19.9% of portfolio in ATEA PHARMACEUTICALS INC.
The fund managers got completely rid off ESSA PHARMA INC (EPIX), IKENA ONCOLOGY INC (IKNA) and MILESTONE PHARMACEUTICALS IN (MIST) stocks. They significantly reduced their stock positions in LISATA THERAPEUTICS INC (CLBS) and ATEA PHARMACEUTICALS INC (AVIR). BML Capital Management, LLC opened new stock positions in CONNECT BIOPHARMA HLDGS LTD, IMAGENEBIO INC (IKNA) and ATHIRA PHARMA INC (ATHA). The fund showed a lot of confidence in some stocks as they added substantially to INSTIL BIO INC (TIL), KEZAR LIFE SCIENCES INC (KZR) and PMV PHARMACEUTICALS INC (PMVP).
BML Capital Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that BML Capital Management, LLC made a return of 8.13% in the last quarter. In trailing 12 months, it's portfolio return was -3.98%.
New Buys
| Ticker | $ Bought |
|---|---|
| connect biopharma hldgs ltd | 1,913,920 |
| imagenebio inc | 1,487,450 |
| athira pharma inc | 1,337,490 |
| target corp | 897,000 |
| arvinas inc | 426,000 |
| mural oncology pub ltd co | 119,025 |
New stocks bought by BML Capital Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| instil bio inc | 20.7 |
| kezar life sciences inc | 13.48 |
| pmv pharmaceuticals inc | 5.84 |
| oramed pharmaceuticals inc | 2.72 |
Additions to existing portfolio by BML Capital Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| lisata therapeutics inc | -47.65 |
| atea pharmaceuticals inc | -1.79 |
BML Capital Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| elevation oncology inc | -2,162,380 |
| essa pharma inc | -7,176,630 |
| connect biopharma hldgs ltd | -1,785,130 |
| milestone pharmaceuticals in | -2,204,020 |
| turnstone biologics corp | -396,116 |
| ikena oncology inc | -5,400,340 |
| athira pharma inc | -975,661 |
| verrica pharmaceuticals inc | -92,583 |
BML Capital Management, LLC got rid off the above stocks
Sector Distribution
BML Capital Management, LLC has about 88.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 88.3 |
| Others | 9.6 |
Market Cap. Distribution
BML Capital Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 85.3 |
| UNALLOCATED | 9.6 |
| NANO-CAP | 3.8 |
Stocks belong to which Index?
About 56% of the stocks held by BML Capital Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 56 |
| Others | 43.2 |
BML Capital Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of BML Capital Management, LLC
BML Capital Management, LLC has 19 stocks in it's portfolio. About 93.9% of the portfolio is in top 10 stocks. AVIR proved to be the most loss making stock for the portfolio. ADVM was the most profitable stock for BML Capital Management, LLC last quarter.
Last Reported on: 10 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics inc | 24.79 | 14,250,000 | 27,075,000 | unchanged | 0.00 | ||
| ADVM | adverum biotechnologies inc | 12.68 | 3,057,530 | 13,850,600 | unchanged | 0.00 | ||
| ARVN | arvinas inc | 0.39 | 50,000 | 426,000 | new | |||
| ASTC | astrotech corp | 0.99 | 220,410 | 1,080,010 | unchanged | 0.00 | ||
| ATHA | athira pharma inc | 1.23 | 323,066 | 1,337,490 | new | |||
| ATHA | athira pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVIR | atea pharmaceuticals inc | 19.85 | 7,473,960 | 21,674,500 | reduced | -1.79 | ||
| CLBS | lisata therapeutics inc | 0.26 | 109,841 | 287,783 | reduced | -47.65 | ||
| CNTB | connect biopharma hldgs ltd | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRVS | corvus pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ELEV | elevation oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EPIX | essa pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| HLVX | hillevax inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IKNA | imagenebio inc | 1.36 | 182,509 | 1,487,450 | new | |||
| IKNA | ikena oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KZR | kezar life sciences inc | 2.57 | 720,787 | 2,811,070 | added | 13.48 | ||
| MIST | milestone pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ORMP | oramed pharmaceuticals inc | 7.66 | 3,167,230 | 8,361,490 | added | 2.72 | ||
| PMVP | pmv pharmaceuticals inc | 6.78 | 5,292,000 | 7,408,800 | added | 5.84 | ||
| TGT | target corp | 0.82 | 10,000 | 897,000 | new | |||